Expert Interview
Reviewing Ocular Therapeutix interim 10-month data from its U.S. Phase 1 clinical trial evaluating OTX-TKI, the company’s axitinib intravitreal hydrogel implant being developed for the treatment of wet age-related macular degeneration
Ticker(s): OCULInstitution: Centre for Eye Research, Australia
- Associate professor of medicine who currently manages 200 patients with wet-AMD
- Senior Research Fellow in CERA’s Clinical Trials Research Centre. Principal investigator in several multi-centre international and national drug trials of new treatments in macular degeneration, diabetic macular oedema and retinal vein occlusion and has written over 60 peer reviewed articles for top ranked journals.
- Section editor for Clinical and Experimental Ophthalmology and is a reviewer for several major ophthalmology journals, including the Archives of Ophthalmology and British Journal of Ophthalmology.
- Conducted research into the treatment and investigation of factors affecting the outcomes of treatment in patients with neovascular age related macular degeneration and diabetic retinopathy.
Please describe your background and clinical practice
Added By: ben_adminHow many patients with wet-AMD do you manage?
Added By: ben_adminWhat are your overall thoughts on Ocular's OTX-TKI data?
Added By: ben_adminWhat future data would convince you that OTX-TKI is first in class?
Added By: ben_adminDo you think slow release implant devices will be the preferred treatment in the future for wet-AMD?
Added By: ben_adminRank your enthusiasm on a scale of 1-10
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
